152 related articles for article (PubMed ID: 38529903)
1. Evaluation of the impact of two C5 genetic variants on C5-eculizumab complex stability at the molecular level.
Peixoto VP; Prudêncio C; Vieira M; Sousa SF
J Biomol Struct Dyn; 2024 Mar; ():1-10. PubMed ID: 38529903
[TBL] [Abstract][Full Text] [Related]
2. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
[TBL] [Abstract][Full Text] [Related]
4. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
[TBL] [Abstract][Full Text] [Related]
6. Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis.
Cheng WY; Fishman J; Yenikomshian M; Mahendran M; Kunzweiler C; Vu JD; Duh MS
Adv Ther; 2024 Jan; 41(1):413-430. PubMed ID: 37999832
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in C5 and poor response to eculizumab.
Nishimura J; Yamamoto M; Hayashi S; Ohyashiki K; Ando K; Brodsky AL; Noji H; Kitamura K; Eto T; Takahashi T; Masuko M; Matsumoto T; Wano Y; Shichishima T; Shibayama H; Hase M; Li L; Johnson K; Lazarowski A; Tamburini P; Inazawa J; Kinoshita T; Kanakura Y
N Engl J Med; 2014 Feb; 370(7):632-9. PubMed ID: 24521109
[TBL] [Abstract][Full Text] [Related]
8. [Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab].
Nishimura JI
Rinsho Ketsueki; 2018; 59(8):1042-1047. PubMed ID: 30185704
[TBL] [Abstract][Full Text] [Related]
9. [Novel anti-complement therapeutics for hemolytic anemia].
Nishimura JI
Rinsho Ketsueki; 2023; 64(6):466-473. PubMed ID: 37407469
[TBL] [Abstract][Full Text] [Related]
10. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.
Hallstensen RF; Bergseth G; Foss S; Jæger S; Gedde-Dahl T; Holt J; Christiansen D; Lau C; Brekke OL; Armstrong E; Stefanovic V; Andersen JT; Sandlie I; Mollnes TE
Immunobiology; 2015 Apr; 220(4):452-9. PubMed ID: 25468724
[TBL] [Abstract][Full Text] [Related]
11. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
12. A patient with paroxysmal nocturnal hemoglobinuria being treated with eculizumab who underwent laparoscopic cholecystectomy: report of a case.
Moriyama M; Nagata T; Yoshioka I; Hashimoto I; Matsui K; Okumura T; Tsukada K
Surg Case Rep; 2015; 1(1):57. PubMed ID: 26366354
[TBL] [Abstract][Full Text] [Related]
13. Treatment of a patient with classical paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome, with complement inhibitor eculizumab: Case Report.
Mandala E; Lafaras C; Goulis I; Tsioni K; Georgopoulou V; Ilonidis G
Hippokratia; 2013 Jan; 17(1):81-4. PubMed ID: 23935352
[TBL] [Abstract][Full Text] [Related]
14. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
Notaro R; Sica M
Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
[TBL] [Abstract][Full Text] [Related]
15. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.
Risitano AM; Notaro R; Marando L; Serio B; Ranaldi D; Seneca E; Ricci P; Alfinito F; Camera A; Gianfaldoni G; Amendola A; Boschetti C; Di Bona E; Fratellanza G; Barbano F; Rodeghiero F; Zanella A; Iori AP; Selleri C; Luzzatto L; Rotoli B
Blood; 2009 Apr; 113(17):4094-100. PubMed ID: 19179465
[TBL] [Abstract][Full Text] [Related]
16. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Wong EK; Kavanagh D
Transl Res; 2015 Feb; 165(2):306-20. PubMed ID: 25468487
[TBL] [Abstract][Full Text] [Related]
17. [The C5 gene polymorphism in patients with PNH].
Nishimura J; Kanakura Y
Rinsho Ketsueki; 2015 Feb; 56(2):103-10. PubMed ID: 25765788
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.
Badri P; Jiang X; Borodovsky A; Najafian N; Kim J; Clausen VA; Goel V; Habtemariam B; Robbie GJ
Clin Pharmacokinet; 2021 Mar; 60(3):365-378. PubMed ID: 33047216
[TBL] [Abstract][Full Text] [Related]
19. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.
Stern RM; Connell NT
Ther Adv Hematol; 2019; 10():2040620719874728. PubMed ID: 31534662
[TBL] [Abstract][Full Text] [Related]
20. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R
J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]